CA2153391A1 - Inducing Cytotoxic T Lymphocyte Responses - Google Patents
Inducing Cytotoxic T Lymphocyte ResponsesInfo
- Publication number
- CA2153391A1 CA2153391A1 CA2153391A CA2153391A CA2153391A1 CA 2153391 A1 CA2153391 A1 CA 2153391A1 CA 2153391 A CA2153391 A CA 2153391A CA 2153391 A CA2153391 A CA 2153391A CA 2153391 A1 CA2153391 A1 CA 2153391A1
- Authority
- CA
- Canada
- Prior art keywords
- particulate
- replicating
- protein antigen
- protein
- mammalian host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 101710151532 Replicating protein Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000036039 immunity Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 210000001236 prokaryotic cell Anatomy 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/917—Vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Abstract
The invention provides compositions and methods for inducing MHC class I-restricted cytotoxic T lymphocyte responses in a mammalian host by immunization with non-replicating protein antigens. The compositions of the invention comprise a particulate-protein complex capable of inducing a class I-restricted CTL response to a protein antigen in a mammal in which the particulate protein complex comprises a particulate component having an average diameter ranging in size from about .5µm to about 6µm linked to a non-replicating protein antigen derived from a tumor cell or from pathogenic organism where CTL response is likely to play an important role in conferring protective immunity in a mammal, with the proviso that the particulate component is not a prokaryotic or eukaryotic cell, or a micellar, multimicellar, or liposome vesicle composed of detergents or lipids. The non-replicating protein antigen is attached to the particle component through a covalent or non-covalent association to form particulate protein antigen complexes and the complexes are administered to a mammalian host in conjunction with a pharmaceutically acceptable excipient, in a CTL-stimulatory amount. The invention also provides non-replicating vaccines and methods of vaccinating a mammalian host against pathogenic diseases or tumors for CTL immunity.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US323393A | 1993-01-11 | 1993-01-11 | |
US08/003,233 | 1993-01-11 | ||
PCT/US1994/000362 WO1994015635A1 (en) | 1993-01-11 | 1994-01-10 | Inducing cytotoxic t lymphocyte responses |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2153391A1 true CA2153391A1 (en) | 1994-07-21 |
CA2153391C CA2153391C (en) | 2000-08-15 |
Family
ID=21704843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002153391A Expired - Lifetime CA2153391C (en) | 1993-01-11 | 1994-01-10 | Inducing cytotoxic t lymphocyte responses |
Country Status (11)
Country | Link |
---|---|
US (2) | US5928647A (en) |
EP (1) | EP0678034B1 (en) |
JP (1) | JPH08505625A (en) |
AT (1) | ATE180407T1 (en) |
AU (1) | AU679041B2 (en) |
CA (1) | CA2153391C (en) |
DE (1) | DE69418699T2 (en) |
DK (1) | DK0678034T3 (en) |
ES (1) | ES2131676T3 (en) |
GR (1) | GR3030568T3 (en) |
WO (1) | WO1994015635A1 (en) |
Families Citing this family (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1217395A (en) * | 1993-12-23 | 1995-07-10 | GFF Gesellschaft zur Forderung der industrie-orientierten Forschung | Immunological response potentiation process |
JP3365635B2 (en) * | 1994-09-23 | 2003-01-14 | ゾナジェン,インコーポレイテッド | Chitosan-induced immune enhancement |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
ES2268182T3 (en) * | 1995-01-17 | 2007-03-16 | The Brigham And Women's Hospital, Inc. | SPECIFIC TRANSEPITELIAL TRANSPORTATION OF IMMUNOGEN RECEIVERS. |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
DE19511276C2 (en) * | 1995-03-27 | 1999-02-18 | Immuno Ag | Adjuvant based on colloidal iron compounds |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6592877B1 (en) * | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6290969B1 (en) * | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US20050003431A1 (en) * | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
EP1275380A1 (en) * | 1997-01-30 | 2003-01-15 | Chiron Corporation | Use of microparticles with adsorbed antigen to stimulate immune responses |
ATE235890T1 (en) * | 1997-01-30 | 2003-04-15 | Chiron Corp | USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE DEFENSE |
US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US7087713B2 (en) * | 2000-02-25 | 2006-08-08 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6254890B1 (en) * | 1997-12-12 | 2001-07-03 | Massachusetts Institute Of Technology | Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
US8143386B2 (en) * | 1999-04-07 | 2012-03-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
JP2003510370A (en) * | 1999-10-07 | 2003-03-18 | コリクサ コーポレイション | Fusion protein of Mycobacterium tuberculosis |
AU7877900A (en) * | 1999-10-13 | 2001-04-23 | Chiron Corporation | Method of obtaining cellular immune responses from proteins |
AU2001256156B2 (en) | 2000-02-23 | 2006-01-05 | Smithkline Beecham Biologicals S.A. | Novel compounds |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US20010036463A1 (en) * | 2000-03-09 | 2001-11-01 | Compans Richard W. | Transcutaneous immunization for large particulate antigens |
CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
MXPA02001323A (en) | 2000-05-10 | 2004-07-16 | Alliance Pharma | Phospholipid-based powders for drug delivery. |
ATE526994T1 (en) | 2000-06-20 | 2011-10-15 | Corixa Corp | MTB32A ANTIGEN FROM MYCOBACTERIA TUBERCULOSIS WITH INACTIVATED PROTEASE ACTIVITY AND FUSION PROTEINS THAT CONTAIN THE ANTIGEN |
AR029540A1 (en) | 2000-06-28 | 2003-07-02 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND THERAPY OF CA NCER DE PULMoN |
WO2002009674A2 (en) * | 2000-07-28 | 2002-02-07 | Inhale Therapeutic Systems, Inc. | Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
AUPR011700A0 (en) * | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
WO2002026212A2 (en) * | 2000-09-28 | 2002-04-04 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
CN1468089B (en) * | 2000-09-28 | 2011-09-21 | 诺华疫苗和诊断公司 | Microparticles for delivery of the heterologous nucleic acids |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
US7618939B2 (en) | 2001-02-15 | 2009-11-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
US20040126900A1 (en) * | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
JP2005504513A (en) | 2001-05-09 | 2005-02-17 | コリクサ コーポレイション | Compositions and methods for treatment and diagnosis of prostate cancer |
CA2452382A1 (en) | 2001-07-10 | 2003-01-23 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
ES2405405T3 (en) | 2001-12-17 | 2013-05-31 | Corixa Corporation | Compositions and procedures for the therapy and diagnosis of inflammatory bowel disease |
US20030219459A1 (en) * | 2002-01-18 | 2003-11-27 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
US7026465B2 (en) | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
CA2478973A1 (en) * | 2002-03-13 | 2003-09-25 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
US20040170606A1 (en) * | 2002-06-07 | 2004-09-02 | Palmer Kenneth E. | Production of peptides in plants as viral coat protein fusions |
US20040033585A1 (en) * | 2002-06-07 | 2004-02-19 | Mccormick Alison A. | Flexible vaccine assembly and vaccine delivery platform |
BR0311995A (en) * | 2002-06-20 | 2005-04-05 | Cytos Biotechnology Ag | Virus-like particles packaged for use as adjuvants: Method of preparation and use |
CN1668637B (en) * | 2002-07-17 | 2010-05-26 | 希托斯生物技术股份公司 | Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
JP5084103B2 (en) * | 2002-07-18 | 2012-11-28 | サイトス バイオテクノロジー アーゲー | Hapten carrier conjugates and uses thereof |
MXPA05000819A (en) * | 2002-07-19 | 2005-08-29 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays. |
WO2004100984A1 (en) * | 2003-05-13 | 2004-11-25 | The University Of Massachusetts | Endogenous adjuvant molecules and uses thereof |
ES2328697T5 (en) | 2003-06-02 | 2017-07-25 | Novartis Vaccines And Diagnostics, Inc. | Immunogenic compositions based on microparticles comprising adsorbed toxoid and an antigen containing a polysaccharide |
CN1835974A (en) | 2003-06-16 | 2006-09-20 | 细胞技术研究与发展公司 | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US9050352B2 (en) * | 2003-10-16 | 2015-06-09 | Stephen John Ralph | Immunomodulating compositions and uses therefor |
ZA200604663B (en) * | 2004-01-20 | 2008-02-27 | Cytos Biotechnology Ag | Particle-induced ghrelin immune response |
WO2006031264A2 (en) | 2004-05-25 | 2006-03-23 | Oregon Health And Science University | Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors |
BRPI0516775A (en) * | 2004-10-25 | 2008-09-23 | Cytos Biotechnology Ag | gastric inhibitor antigen (gip) polypeptide assays and their uses |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
AU2006229968A1 (en) | 2005-03-31 | 2006-10-05 | Corixa Corporation | Vaccines against Chlamydial infection |
KR20150036658A (en) | 2005-04-29 | 2015-04-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Novel method for preventing or treating m tuberculosis infection |
US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
CA2648099C (en) | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
US8524454B2 (en) | 2006-04-07 | 2013-09-03 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US7702468B2 (en) | 2006-05-03 | 2010-04-20 | Population Diagnostics, Inc. | Evaluating genetic disorders |
US10522240B2 (en) | 2006-05-03 | 2019-12-31 | Population Bio, Inc. | Evaluating genetic disorders |
US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
WO2008019142A2 (en) * | 2006-08-04 | 2008-02-14 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
WO2008098165A2 (en) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
JP5391387B2 (en) * | 2007-03-09 | 2014-01-15 | 小川 一文 | Magnetosensitive drug and method for producing the same |
WO2008124639A2 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
US8932558B2 (en) * | 2007-10-05 | 2015-01-13 | Plaxgen Inc | Multi-subunit biological complexes for treatment of plaque-associated diseases |
AU2008314647B2 (en) | 2007-10-12 | 2013-03-21 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US8268887B2 (en) | 2008-10-08 | 2012-09-18 | Feng Xu | Drug conjugates and methods of use thereof |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
EA201791383A1 (en) | 2009-05-27 | 2018-06-29 | Селекта Байосайенсиз, Инк. | NANOSEELS HAVE COMPONENTS WITH DIFFERENT RELEASE RATES |
US20110038852A1 (en) * | 2009-06-10 | 2011-02-17 | 3-V Biosciences, Inc. | Antivirals that target transporters, carriers, and ion channels |
CN107617110A (en) * | 2009-08-26 | 2018-01-23 | 西莱克塔生物科技公司 | The composition of inducing T cell auxiliary |
US20120244185A1 (en) | 2009-09-16 | 2012-09-27 | Vaxart ,Inc. | Immunization strategy to prevent h1n1 infection |
KR20170098985A (en) | 2009-11-19 | 2017-08-30 | 솔리스 바이오다인 | Compositions for increasing polypeptide stability and activity, and related methods |
DK2528621T3 (en) | 2010-01-27 | 2017-01-02 | Glaxosmithkline Biologicals Sa | Modified tuberculosis antigens |
NO2575876T3 (en) | 2010-05-26 | 2018-05-05 | ||
US8862410B2 (en) | 2010-08-02 | 2014-10-14 | Population Diagnostics, Inc. | Compositions and methods for discovery of causative mutations in genetic disorders |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | Modified nicotinic compounds and related methods |
EP2683244B1 (en) | 2011-03-08 | 2017-02-01 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
EA201791679A1 (en) | 2011-04-29 | 2018-09-28 | Селекта Байосайенсиз, Инк. | TOLEROGENIC SYNTHETIC NANO CARRIERS |
US20150030586A1 (en) | 2011-06-21 | 2015-01-29 | Sarah Ellen Warren | Compositions and methods for the therapy and diagnosis of cancer |
EP2736537A4 (en) | 2011-07-29 | 2015-04-15 | Selecta Biosciences Inc | Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
US10221454B2 (en) | 2011-10-10 | 2019-03-05 | The Hospital For Sick Children | Methods and compositions for screening and treating developmental disorders |
WO2013067451A2 (en) | 2011-11-04 | 2013-05-10 | Population Diagnostics Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
CN107880101B (en) | 2011-11-11 | 2021-12-21 | 弗雷德哈钦森癌症研究中心 | T cell immunotherapy targeting cyclin A1 against cancer |
WO2013120018A1 (en) | 2012-02-09 | 2013-08-15 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
BR112014021388A2 (en) | 2012-02-29 | 2017-07-18 | Ethicon Endo Surgery Inc | microbiota compositions and methods related thereto |
WO2014043519A1 (en) | 2012-09-14 | 2014-03-20 | Population Diagnostics Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
EP2900835A4 (en) | 2012-09-27 | 2016-05-11 | Population Diagnotics Inc | Methods and compositions for screening and treating developmental disorders |
GB2535034A (en) | 2013-07-21 | 2016-08-10 | Whole Biome Inc | Methods and systems for microbiome characterization, monitoring and treatment |
JP6820097B2 (en) | 2013-12-20 | 2021-01-27 | サギメット バイオサイエンシーズ インコーポレイテッド | Heterocyclic modulators of lipid synthesis and their combinations |
MX2016008841A (en) | 2014-01-07 | 2016-10-13 | 3-V Biosciences Inc | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections. |
CN113403338A (en) | 2014-03-28 | 2021-09-17 | 华盛顿大学商业中心 | Breast and ovarian cancer vaccines |
EP3169699A4 (en) | 2014-07-18 | 2018-06-20 | The University of Washington | Cancer vaccine compositions and methods of use thereof |
US10724096B2 (en) | 2014-09-05 | 2020-07-28 | Population Bio, Inc. | Methods and compositions for inhibiting and treating neurological conditions |
WO2016054240A1 (en) | 2014-09-30 | 2016-04-07 | Sean Dalziel | Fixed dose combinations for the treatment of viral diseases |
CN113730442A (en) | 2014-10-31 | 2021-12-03 | 潘德勒姆治疗公司 | Methods and compositions relating to microbial treatment and diagnosis of disorders |
JP6758314B2 (en) | 2015-03-19 | 2020-09-23 | サギメット バイオサイエンシーズ インコーポレイテッド | Heterocyclic regulator of lipid synthesis |
JP6912394B2 (en) | 2015-06-12 | 2021-08-04 | バクサート インコーポレイテッド | Formulations for small intestinal delivery of RSV and norovirus antigens |
CN109415445A (en) | 2016-05-04 | 2019-03-01 | 阿比利塔生物公司 | It is used to prepare the method and platform of membrane-spanning proteins |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
US11725232B2 (en) | 2016-10-31 | 2023-08-15 | The Hong Kong University Of Science And Technology | Compositions, methods and kits for detection of genetic variants for alzheimer's disease |
US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
CA3073838A1 (en) | 2017-08-30 | 2019-03-07 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
MX2020013772A (en) | 2018-06-29 | 2021-05-27 | Wuhan Neurophth Biotechnology Ltd Company | Compositions and methods for treating leber's hereditary optic neuropathy. |
FI3625368T3 (en) | 2018-08-08 | 2023-01-13 | Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing | |
CA3109432A1 (en) | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
JP7320601B2 (en) | 2018-09-11 | 2023-08-03 | 上▲海▼市公共▲衛▼生▲臨▼床中心 | Broad-spectrum anti-influenza vaccine immunogen and its use |
TW202120551A (en) | 2019-08-12 | 2021-06-01 | 美商普瑞諾生物科技公司 | Methods and compositions for promoting and potentiating t‐cell mediated immune responses through adcc targeting of cd39 expressing cells |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
CN113025633A (en) | 2019-12-09 | 2021-06-25 | 武汉纽福斯生物科技有限公司 | Nucleic acid for coding human NADH dehydrogenase subunit 1 protein and application thereof |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
WO2023280157A1 (en) | 2021-07-05 | 2023-01-12 | 武汉纽福斯生物科技有限公司 | Construction and use of anti-vegf antibody in-vivo expression system |
TW202332694A (en) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | Serum half-life extended pd-l1 binding polypeptides |
TW202334196A (en) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1 binding polypeptides |
WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK143689C (en) * | 1975-03-20 | 1982-03-15 | J Kreuter | PROCEDURE FOR THE PREPARATION OF AN ADVERTISED VACCINE |
US4804624A (en) * | 1982-05-21 | 1989-02-14 | The University Of Tennessee Research Corporation | Passive agglutination assay for pseudorabies antibody |
US5417986A (en) * | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
GB2160312B (en) | 1984-04-13 | 1987-09-16 | South African Inventions | Adjuvant for immunisation |
US5078998A (en) | 1985-08-02 | 1992-01-07 | Bevan Michael J | Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen |
GB8610983D0 (en) | 1986-05-06 | 1986-06-11 | Connaught Lab | Enhancement of antigen immunogenicity |
US5194254A (en) | 1986-05-06 | 1993-03-16 | Connaught Laboratories Limited | Enhancement of antigen immunogenicity |
US5041385A (en) | 1986-11-01 | 1991-08-20 | Oxford Gene Systems Limited | Vector expressing fusion proteins and particles |
US4918166A (en) | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
US5008116A (en) | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
WO1990007322A1 (en) | 1988-12-19 | 1990-07-12 | David Gordon | Diagnosis and treatment of viral effects |
US5021551A (en) | 1989-01-18 | 1991-06-04 | Washington University | Method of enhancing peptide immunogenicity |
US5045320A (en) * | 1989-03-23 | 1991-09-03 | Medical Biology Institute | Large multivalent immunogen |
ES2096650T3 (en) * | 1990-05-10 | 1997-03-16 | Dana Farber Cancer Inst Inc | IMPROVEMENT OF THE ASSOCIATION OF EXOGENOUS PEPTIDES WITH MHC CLASS I MOLECULES IN CELLS OF THE IMMUNE SYSTEM. |
US5219577A (en) | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
WO1992019263A1 (en) | 1991-04-24 | 1992-11-12 | The United States Of America, As Represented By The Secretary Of The Army | Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
WO1992021376A1 (en) | 1991-06-06 | 1992-12-10 | Med Immune, Inc. | Induction of ctl responses to foreign antigens expressed in mycobacteria |
FR2682114B1 (en) * | 1991-10-03 | 1996-02-23 | Pasteur Merieux Serums Vacc | SUB-UNIT VACCINE AGAINST NEISSERIA MENINGITIDIS AND SUB-UNITS CORRESPONDING TO PURIFIED STATE. |
ATE212540T1 (en) | 1991-11-26 | 2002-02-15 | Jenner Technologies | ANTITUMOR VACCINES |
-
1994
- 1994-01-10 AU AU60865/94A patent/AU679041B2/en not_active Expired
- 1994-01-10 WO PCT/US1994/000362 patent/WO1994015635A1/en active IP Right Grant
- 1994-01-10 JP JP6516291A patent/JPH08505625A/en active Pending
- 1994-01-10 ES ES94907191T patent/ES2131676T3/en not_active Expired - Lifetime
- 1994-01-10 CA CA002153391A patent/CA2153391C/en not_active Expired - Lifetime
- 1994-01-10 US US08/481,327 patent/US5928647A/en not_active Expired - Lifetime
- 1994-01-10 AT AT94907191T patent/ATE180407T1/en active
- 1994-01-10 DE DE69418699T patent/DE69418699T2/en not_active Expired - Lifetime
- 1994-01-10 DK DK94907191T patent/DK0678034T3/en active
- 1994-01-10 EP EP94907191A patent/EP0678034B1/en not_active Expired - Lifetime
-
1995
- 1995-04-18 US US08/425,679 patent/US6328972B1/en not_active Expired - Lifetime
-
1999
- 1999-06-17 GR GR990401651T patent/GR3030568T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
GR3030568T3 (en) | 1999-10-29 |
WO1994015635A1 (en) | 1994-07-21 |
DK0678034T3 (en) | 1999-11-08 |
EP0678034A1 (en) | 1995-10-25 |
AU6086594A (en) | 1994-08-15 |
US6328972B1 (en) | 2001-12-11 |
DE69418699T2 (en) | 1999-09-30 |
EP0678034B1 (en) | 1999-05-26 |
CA2153391C (en) | 2000-08-15 |
ES2131676T3 (en) | 1999-08-01 |
DE69418699D1 (en) | 1999-07-01 |
ATE180407T1 (en) | 1999-06-15 |
US5928647A (en) | 1999-07-27 |
JPH08505625A (en) | 1996-06-18 |
AU679041B2 (en) | 1997-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2153391A1 (en) | Inducing Cytotoxic T Lymphocyte Responses | |
Hunter et al. | Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha | |
US6726910B2 (en) | Immuno-reactive peptide CTL epitopes of human cytomegalovirus | |
CA2123580A1 (en) | Antigen of hybrid m protein and carrier for group a streptococcal vaccine | |
CA2033640A1 (en) | Vaccines against cancer and infectious diseases | |
CA2143823A1 (en) | Retro-, inverso - and retro-inverso synthetic peptide analogues | |
ES8406199A1 (en) | Materials and methods for herpes simplex virus vaccination. | |
CA2232344A1 (en) | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells | |
CA2014033A1 (en) | Compositions and treatments for pneumonia in animals | |
CA2140624A1 (en) | P53 vaccine | |
CA2055615A1 (en) | Monoclonal antibodies for inducing tolerance | |
Salabert et al. | Intradermal injection of an anti‐Langerin‐HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo | |
CA2372181A1 (en) | Adjuvant combination formulations | |
Grufman et al. | Innate and adaptive immunity to tumors: IL‐12 is required for optimal responses | |
JP4666761B2 (en) | Immunomodulators for vaccines | |
Chiarantini et al. | Red blood cells as delivery system for recombinant HSV-1 glycoprotein B: immunogenicity and protection in mice | |
Unanue et al. | Role of macrophages in delayed hypersensitivity: I. Induction with macrophage-bound antigen | |
FI932759A0 (en) | Enhancement of IL-4 For the purpose of vaccinia immunogenic generic immunoreaction | |
EP0427768A1 (en) | Polypeptide pertussis toxin vaccine | |
CA2399432A1 (en) | Cytotoxic t lymphocytes activated by dendritic cell hybrids | |
US4622223A (en) | Broad spectrum vaccine against gonorrhea | |
Hatzifoti et al. | Liposomal co-entrapment of CD40mAb induces enhanced IgG responses against bacterial polysaccharide and protein | |
Allison | Antigens and adjuvants for a new generation of vaccines | |
Knittel et al. | Heparan sulfates targeting increases MHC class I-and MHC class II-restricted antigen presentation and CD8+ T-cell response | |
EP0783892B1 (en) | Method to increase and modify immune responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140110 |